662 related articles for article (PubMed ID: 25933931)
21. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy.
Lange SA; Ebner B; Wess A; Kögel M; Gajda M; Hitschold T; Jung J
Clin Res Cardiol; 2012 Jun; 101(6):415-26. PubMed ID: 22249492
[TBL] [Abstract][Full Text] [Related]
22. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
[TBL] [Abstract][Full Text] [Related]
23. Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.
Jacquinot Q; Paget-Bailly S; Fumoleau P; Romieu G; Pierga JY; Espié M; Lortholary A; Nabholtz JM; Mercier CF; Pauporté I; Henriques J; Pivot X
Breast; 2018 Oct; 41():1-7. PubMed ID: 29913374
[TBL] [Abstract][Full Text] [Related]
24. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
[TBL] [Abstract][Full Text] [Related]
25. Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab.
Song L; Brezden-Masley C; Ramanan V; Ghugre N; Barfett JJ; Chan KKW; Haq R; Petrella T; Dhir V; Jimenez-Juan L; Chacko BR; Kotha V; Connelly KA; Yan AT
Am J Cardiol; 2019 Apr; 123(7):1173-1179. PubMed ID: 30683420
[TBL] [Abstract][Full Text] [Related]
26. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
Abouegylah M; Braunstein LZ; Alm El-Din MA; Niemierko A; Salama L; Elebrashi M; Edgington SK; Remillard K; Napolitano B; Naoum GE; Sayegh HE; Gillespie T; Farouk M; Ismail AA; Taghian AG
Breast Cancer Res Treat; 2019 Feb; 174(1):179-185. PubMed ID: 30478787
[TBL] [Abstract][Full Text] [Related]
28. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
29. Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients.
Sayan M; Abou Yehia Z; Gupta A; Toppmeyer D; Ohri N; Haffty BG
Front Oncol; 2019; 9():970. PubMed ID: 31632906
[No Abstract] [Full Text] [Related]
30. Early detection of subclinical left ventricular dysfunction after breast cancer radiation therapy using speckle-tracking echocardiography: association between cardiac exposure and longitudinal strain reduction (BACCARAT study).
Walker V; Lairez O; Fondard O; Pathak A; Pinel B; Chevelle C; Franck D; Jimenez G; Camilleri J; Panh L; Broggio D; Derreumaux S; Bernier MO; Laurier D; Ferrières J; Jacob S
Radiat Oncol; 2019 Nov; 14(1):204. PubMed ID: 31727075
[TBL] [Abstract][Full Text] [Related]
31. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
[TBL] [Abstract][Full Text] [Related]
33. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy.
Erven K; Florian A; Slagmolen P; Sweldens C; Jurcut R; Wildiers H; Voigt JU; Weltens C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1172-8. PubMed ID: 23149005
[TBL] [Abstract][Full Text] [Related]
34. Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients.
Dores H; Abecasis J; Correia MJ; Gândara F; Fonseca C; Azevedo J; Arroja I; Martins A; Mendes M
Arq Bras Cardiol; 2013 Apr; 100(4):328-32. PubMed ID: 23525273
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
36. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
37. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
[TBL] [Abstract][Full Text] [Related]
38. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy.
Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Chow CM; Thavendiranathan D; Haq R; Barfett JJ; Petrella TM; Connelly KA; Yan AT
Int J Cardiol; 2018 Jun; 261():228-233. PubMed ID: 29555336
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
[TBL] [Abstract][Full Text] [Related]
40. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
